U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27FN4O2
Molecular Weight 410.4854
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE

SMILES

Cc1c(CCN2CCC(CC2)c3c4ccc(cc4on3)F)c(=O)n5CCCCc5n1

InChI

InChIKey=RAPZEAPATHNIPO-UHFFFAOYSA-N
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

HIDE SMILES / InChI

Description

Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is FDA approved for the treatment of schizophrenia, bipolar mania, irritability associated with autistic disorder. Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Vice versa, Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Common adverse reactions include increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia , metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, potential for cognitive and motor impairment, seizures, dysphagia, priapism, disruption of body temperature regulation.

Originator

Curator's Comment:: # Janssen Pharmaceutica N.V.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

757123200000
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

757123200000
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

757123200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.77 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
83.1 ng × h/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
53.86 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.88 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Dizziness, Agitation...
AEs leading to
discontinuation/dose reduction:
Dizziness (1%)
Agitation (1%)
Somnolence (0.5%)
Hypotension postural (0.5%)
Tachycardia (0.5%)
Akathisia (1%)
Sources:
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Parkinsonism, Somnolence...
AEs leading to
discontinuation/dose reduction:
Parkinsonism (0.4%)
Somnolence (0.2%)
Dizziness (0.2%)
Dystonia (0.2%)
SGOT increased (0.2%)
SGPT increased (0.2%)
Sources:
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Dizziness, Nausea...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.4%)
Nausea (1.4%)
Agitation (1.1%)
Parkinsonism (0.8%)
Somnolence (0.8%)
Dystonia (0.5%)
Abdominal pain (0.5%)
Hypotension postural (0.3%)
Tachycardia (0.3%)
Sources:
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Disc. AE: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Somnolence (2%)
Dizziness (2%)
Anorexia (1%)
Anxiety (1%)
Ataxia (1%)
Hypotension (1%)
Palpitation (1%)
Sources:
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Disc. AE: Somnolence, Nausea...
AEs leading to
discontinuation/dose reduction:
Somnolence (5%)
Nausea (3%)
Abdominal pain (2%)
Vomiting (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension postural 0.5%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Somnolence 0.5%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Tachycardia 0.5%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Agitation 1%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Akathisia 1%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 1%
Disc. AE
16 mg 1 times / day multiple, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 0.2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
Dystonia 0.2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
SGOT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
SGPT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
Somnolence 0.2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
Parkinsonism 0.4%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
Hypotension postural 0.3%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Tachycardia 0.3%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Abdominal pain 0.5%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Dystonia 0.5%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Parkinsonism 0.8%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Somnolence 0.8%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Agitation 1.1%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 1.4%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 1.4%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
Anorexia 1%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Anxiety 1%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Ataxia 1%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Hypotension 1%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Palpitation 1%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Dizziness 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Somnolence 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Abdominal pain 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Vomiting 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Nausea 3%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Somnolence 5%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [IC50 38.1 uM]
weak
no (co-administration study)
Comment: RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP2D6
Page: 37
yes [IC50 15.78 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Fluoxetine and paroxetine (CYP 2D6 inhibitors) have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold, respectively
Page: 36
minor
minor
yes (co-administration study)
Comment: Carbamazepine co-administration with oral RISPERDAL decreased the steady-state plasma concentrations of risperidone by about 50%;
Page: 4
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
2000 Dec
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
2000 Dec 15
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.
2000 Jul
[Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
2000 Jul-Aug
Acute confusional states during treatment with risperidone.
2000 Jun
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
2000 Jun
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
2000 May
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
2000 May
[Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy].
2000 May
Lack of specific effects of selective D(1) and D(2) dopamine antagonists vs. risperidone on morphine-induced hyperactivity.
2000 May
Risperidone implicated in the onset of tardive dyskinesia in a young woman.
2000 May
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
2000 Nov
Risperidone-associated hyperprolactinemia.
2000 Nov-Dec
The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
2000 Oct
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
2000 Oct
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
2000 Sep
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
2000 Sep
Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia.
2000 Spring
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
2001
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
2001
Antipsychotic medications and the elderly: effects on cognition and implications for use.
2001
Olanzapine: an updated review of its use in the management of schizophrenia.
2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
2001
Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone.
2001 Apr
Novel treatments for bipolar disorder.
2001 Apr
Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states.
2001 Apr
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
2001 Feb
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
2001 Feb
Priapism associated with polypharmacy.
2001 Feb
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
2001 Feb
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.
2001 Feb
Combination risperidone and quetiapine therapy in refractory schizophrenia.
2001 Feb
A case of risperidone-induced stuttering.
2001 Feb
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
2001 Feb
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
2001 Feb
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
2001 Jan
Acute and long-term treatment of catatonia with risperidone.
2001 Jan
Bodyweight gain with atypical antipsychotics. A comparative review.
2001 Jan
Risperidone-induced cholestatic hepatitis.
2001 Jan
Does risperidone have a place in the treatment of nonschizophrenic patients?
2001 Jan
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
2001 Jan 1
[Viewpoint of schizophrenic patients: a European survey].
2001 Jan-Feb
Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice.
2001 Jun
Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment.
2001 Mar
The evaluation of multiple surrogate endpoints.
2001 Mar
Fixed-dosed risperidone in mania: an open experimental trial.
2001 Mar
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.
2001 Mar
Estrogen - a potential treatment for schizophrenia.
2001 Mar 1
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
2001 Mar 1
Short-term inpatient pharmacotherapy of schizophrenia.
2001 May-Jun
Patents

Sample Use Guides

Initial dosing is generally 2 mg/day. Dose increases should then occur at intervals not less than 24 hours, in increments of 1–2 mg/day, as tolerated, to a recommended dose of 4–8 mg/day. Effective dose range - 0.5-16 mg (disease dependent).
Route of Administration: Other
Measurement of ATP contents in the neuronal cell line showed significantly increased levels after a 24-h treatment with 25 microg/mL risperidone.
Name Type Language
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
RISPERIDONE [EP MONOGRAPH]
Common Name English
R-64766
Code English
R 64 766
Code English
RISPERIDONE [WHO-DD]
Common Name English
RISPERIDONE [USAN]
Common Name English
RISPERIDONE [USP MONOGRAPH]
Common Name English
N05AX08
Code English
RISPERIDONE [ORANGE BOOK]
Common Name English
R-64,766
Code English
PERSERIS
Brand Name English
RISPERIDONE [HSDB]
Common Name English
RISPERIDONE [USP-RS]
Common Name English
RISPERIDONE [MART.]
Common Name English
RCN3028
Code English
RISPERDAL
Brand Name English
RCN-3028
Code English
RISPERIDONE [JAN]
Common Name English
R-64-766
Code English
NSC-759895
Code English
RISPERIDONE [EP]
Common Name English
LY-03004
Code English
RISPERIDONE [INN]
Common Name English
RISPERIDONE [USP]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-
Systematic Name English
RISPERIDONE [VANDF]
Common Name English
RISPERIDONE [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AX08
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
WHO-VATC QN05AX08
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
LIVERTOX 852
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
FDA ORPHAN DRUG 326110
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL85
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
LACTMED
Risperidone
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
EPA CompTox
106266-06-2
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
DRUG CENTRAL
2389
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
HSDB
7580
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
MERCK INDEX
M9631
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY Merck Index
PUBCHEM
5073
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
WIKIPEDIA
RISPERIDONE
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
MESH
D018967
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
INN
6085
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
EVMPD
SUB10335MIG
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
USP_CATALOG
1604654
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY USP-RS
CAS
106266-06-2
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
RXCUI
35636
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C29416
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
IUPHAR
96
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
DRUG BANK
DB00734
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
FDA UNII
L6UH7ZF8HC
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY